A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Phase 2
252
about 2.2 years
18–70
36 sites in AL, AZ, CA +16
What this study is about
Researchers are testing a treatment called PF-07275315 for people with moderate-to-severe asthma. The trial is seeking participants who are 18 to 70 years old and have had moderate-to-severe asthma for at least 12 months that is not well controlled. Participants will receive PF-07275315 or a placebo, which is an inactive substance that looks like the medicine being studied. The treatment will be given as multiple shots in the clinic over the course of 12 weeks. It will last about 9.5 months and involve 10 visits to the clinic.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take PF-07275315
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12, Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and AEs/SAEs leading to treatment discontinuation
Secondary: Change from baseline in Asthma Control Questionnaire-5 (ACQ-5) total score at Week 12, Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) global score at Week 12, Change from baseline in post-bronchodilator % Predicted FEV1 at all time points, Change from baseline in post-bronchodilator % Predicted FVC at all time points, Change from baseline in post-bronchodilator FEV1 at all time points, Change from baseline in post-bronchodilator FEV1/FVC Ratio at all time points, Change from baseline in post-bronchodilator FVC at all time points, Change from baseline in pre-bronchodilator % Predicted FEV1 at all time points
Respiratory